10177-24-9

Basic information

• Product Name: 5-CHLORO-2-(CHLOROMETHYL)PYRIDINE
• Synonyms: 5-CHLORO-2-(CHLOROMETHYL)PYRIDINE;2-ChloroMethyl-5-chloropyridine;Pyridine, 5-chloro-2-(chloroMethyl)-;5-chloro-pyridin-2-ylmethyl chloride;5-Chloro-2-(chloromethyl)
• CAS NO: 10177-24-9
• Molecular Formula: C₆H₅Cl₂N
• Molecular Weight: 162.02
• Mol File: 10177-24-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 212.967 °C at 760 mmHg
• Flash Point: 102.657 °C
• Appearance: /
• Density: 1.325 g/cm³
• Vapor Pressure: 0.245mmHg at 25°C
• Refractive Index: 1.551
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 1.43±0.22(Predicted)
• CAS DataBase Reference: 5-CHLORO-2-(CHLOROMETHYL)PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-2-(CHLOROMETHYL)PYRIDINE(10177-24-9)
• EPA Substance Registry System: 5-CHLORO-2-(CHLOROMETHYL)PYRIDINE(10177-24-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 10177-24-9(Hazardous Substances Data)

Usage

General Description

5-CHLORO-2-(CHLOROMETHYL)PYRIDINE is a chlorinated pyridine compound with the chemical formula C6H5Cl2N. It is a colorless to pale yellow liquid that is used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. 5-CHLORO-2-(CHLOROMETHYL)PYRIDINE is known for its versatile chemical reactivity and is often used as a building block in organic synthesis. It is also utilized as a reagent in the preparation of various heterocyclic compounds and as a precursor in the production of agrochemicals and pharmaceuticals. Additionally, 5-CHLORO-2-(CHLOROMETHYL)PYRIDINE is known for its potential role as an intermediate in the production of dyes, pigments, and other specialty chemicals. Due to its high reactivity and potential health hazards, it is important to handle this compound with proper safety precautions and under controlled conditions.

InChI:InChI=1/C6H5Cl2N/c7-3-6-2-1-5(8)4-9-6/h1-2,4H,3H2

Upstream product

• 89809-64-3 2-cyano-5-chloropyridine 
• 128073-03-0 4-chloronicotinoyl chloride 
• 132308-19-1 methyl 5-chloropyridine-2-carboxylate 
• 86873-60-1 5-chloropicolinic acid 
• 52313-58-3 5-chloro-2-methylpyridine-N-oxide 
• 31181-73-4 2-acetoxymethyl-5-chloro-pyridine 
• 209526-98-7 (5-chloro-2-pyridinyl)methanol 

Relevant articles and documents

1,4,9-Triazaspiro[5.5]undecan-2-one Derivatives as Potent and Selective METTL3 Inhibitors

N6-methyladenosine (m6A) is the most frequent of the 160 RNA modifications reported so far. Accumulating evidence suggests that the METTL3/METTL14 protein complex, part of the m6A regulation machinery, is a key player in a variety of diseases including several types of cancer, type 2 diabetes, and viral infections. Here we report on a protein crystallography-based medicinal chemistry optimization of a METTL3 hit compound that has resulted in a 1400-fold potency improvement (IC50 of 5 nM for the lead compound 22 (UZH2) in a time-resolved F?rster resonance energy transfer (TR-FRET) assay). The series has favorable ADME properties as physicochemical characteristics were taken into account during hit optimization. UZH2 shows target engagement in cells and is able to reduce the m6A/A level of polyadenylated RNA in MOLM-13 (acute myeloid leukemia) and PC-3 (prostate cancer) cell lines.

5-lipoxygenase-activating protein (FLAP) inhibitors. Part 4: Development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin- 2-ylmethoxy)-1 H -indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor

The potent 5-lipoxygenase-activating protein (FLAP) inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2- ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid 11cc is described (AM803, now GSK2190915). Building upon AM103 (1) (Hutchinson et al. J. Med Chem.2009, 52, 5803-5815; Stock et al. Bioorg. Med. Chem. Lett. 2010, 20, 213-217; Stock et al. Bioorg. Med. Chem. Lett.2010, 20, 4598-4601), SAR studies centering around the pyridine moiety led to the discovery of compounds that exhibit significantly increased potency in a human whole blood assay measuring LTB4 inhibition with longer drug preincubation times (15 min vs 5 h). Further studies identified 11cc with a potency of 2.9 nM in FLAP binding, an IC50 of 76 nM for inhibition of LTB4 in human blood (5 h incubation) and excellent preclinical toxicology and pharmacokinetics in rat and dog. 11cc also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. This compound has successfully completed phase 1 clinical studies in healthy volunteers and is currently undergoing phase 2 trials in asthmatic patients.

Heterocycles substituted pyridine derivatives and antifungal agent containing thereof

An object of the present invention is to provide an antifungal agent which has excellent antifungal effects and is superior in terms of its physical properties, safety and metabolic stability. According to the present invention, there is disclosed a compound represented by the following formula (I), or a salt thereof: wherein R1 represents a hydrogen atom, a halogen atom, an amino group, a C1-6 alkyl group, a C1-6 alkoxy group or a C1-6 alkoxy C1-6 alkyl group; R2 represents a hydrogen atom, a C1-6 alkyl group, an amino group or a di C1-6 alkylamino group; one of X and Y is a nitrogen atom while the other is a nitrogen atom or an oxygen atom; ring A represents a 5- or 6-member heteroaryl ring or a benzene ring which may have a halogen atom, or 1 or 2 C1-6 alkyl groups; Z represents a single bond, a methylene group, an ethylene group, an oxygen atom, a sulfur atom, —CH2O—, —OCH2—, —NH—, —CH2NH—, —NHCH2—, —CH2S—, or —SCH2—; R3 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group, a C3-8 cycloalkyl group, a C6-10 aryl group, a 5- or 6-member heteroaryl group, or 5- or 6-member non-aromatic heterocyclic group which may have 1 or 2 substituents; and R4 represents a hydrogen atom or a halogen atom.